Combretastatin A4

Catalog No.S7783

For research use only.

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Combretastatin A4 Chemical Structure

CAS No. 117048-59-6

Selleck's Combretastatin A4 has been cited by 3 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Other Microtubule Associated Products

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{G4c2N6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJHNMVUWOLUWgcYVt[W6xbXGgZ4VtdCCuaX7ld{whTUR3ME2zMlAxTS1yODFOwG0> MoXENVg4PTN3MB?=
A-549 NVzlWmNPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NETQPYZEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBCNTV2OTDseY5oKGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwMkDFMVA3KM7:TR?= NGL5N3kyQDd3M{Ww
MCF-7 MnrJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2nzbmN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1ETi15IHLy[YF{fCClYYLjbY5wdWFiY3XscEBtcW6nczygSWQ2OD1|LkiwSU0xPiEQvF2= NEj6NZAyQDd3M{Ww
HT-29 MlvYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHm3W|NEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBJXC1{OTDjc4xwdiCjZHXuc4NiemOrbn;tZUBk\WyuIHzpcoV{NCCHREWwQVEvOjCHLUC2JO69VQ>? M2rlcFE5PzV|NUC=
MLM melanoma cell MlvhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkPpR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWxOKG2nbHHuc41iKGOnbHygcIlv\XNuIFXEOVA:OS52MFWtNFYh|ryP M1fZRVE5PzV|NUC=
M14 MVvDfZRwfG:6aXPpeJkh[XO|YYm= NF;iWFRKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhf2G|IITld5Rm\CCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINidmOncjCoUVE1MSClZXzsJIxqdmVuIFfJOVA:OC5yMECxJO69VQ>? NX;WUJY{OTJ5Mkm2OFA>
SK-OV3 Mm\QR5l1d3SxeHnjbZR6KGG|c3H5 Mn:yTY4hfmm2cn:gZ5l1d3SxeHnjJIFkfGm4aYT5JJRme3SnZDDh[4FqdnO2IHj1cYFvKG:4YYLpZY4h[2GwY3XyJEhUUy2RVkOpJINmdGxibHnu[UwhT0l3ME2wMlAxODFizszN Mn;ZNVI4Ojl4NEC=
HL60 cells Mmf2R5l1d3SxeHnjbZR6KGG|c3H5 NH62b4g4OiCq M4HlZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxODFizszN NVK1VWZLOjB5M{GzOVU>
SK-OV-3 NXvyc2F1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFe2OII1QCCq Mo\hS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2suV1ZvMzDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwNVMh|ryP M{jtb|E5PzJ{MUK3
HepG2 cells MW\DfZRwfG:6aXPpeJkh[XO|YYm= NXn2b49xS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFnDOVA:OC5yMECxOEDPxE1? M3LTRlE4OTJ5ME[x
ZR-75-1 M3njUGN6fG:2b4jpZ4l1gSCjc4PhfS=> M37IR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KFqULUe1MVEh[2WubDDsbY5mNCCLQ{WwQVAvODByMkSg{txO M3:1O|E4OjR7NkS5
HeLa cell Moi5R5l1d3SxeHnjbZR6KGG|c3H5 MmX2R5l1d3SxeHnjbZR6KGGpYXnud5QhUGWOYTDj[YxtKGyrbnWsJGlEPTB;MD6wNFA{KM7:TR?= M3jBPVE4OjR7NkS5
HCT116 cell MVnDfZRwfG:6aXPpeJkh[XO|YYm= MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBJS1RzMU[gZ4VtdCCuaX7lMEBKSzVyPUCuNFAxOzVizszN NHHZXGMyPzJ2OU[0PS=>
KBV1 cells MUnDfZRwfG:6aXPpeJkh[XO|YYm= MUK3NkBp NX2xeHBSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hfmmwYnzhd5RqdmVvcnXzbZN1[W62IFvCWlEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNFQh|ryP NV20TZJqOjB5M{GzOVU>
SKOV3 Mn34R5l1d3SxeHnjbZR6KGG|c3H5 MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC0NkDPxE1? NFSyV5QzPDBzNkCwNi=>
SKOV3 cells MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MY\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT29XOyClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuNFAxPDJizszN MljxNlM4PzJ|MEm=
HeLa cells NWPPSWVTS3m2b4TvfIlkcXS7IHHzd4F6 NWLw[WI{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFA2OSEQvF2= NGflbI8yQTh5OUe1PC=>
DU145 cells MmLPR5l1d3SxeHnjbZR6KGG|c3H5 MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC1OEDPxE1? M3m2NVI1ODF4MECy
DU145 cells MlnZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mmf0S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlAxODV2IN88US=> NW\mbYxYOjN5N{KzNFk>
SK-N-BE MljaVJJwdGmoZYLheIlwdiCjc4PhfS=> M{jsTVczKGh? NX\Ie|RWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hW0tvTj3CSUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVgh|ryP NXi3SYNJOjJ|Mkm1OlE>
NCIH460 cells MWnDfZRwfG:6aXPpeJkh[XO|YYm= M1TGPFQ5KGh? MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2lJPDZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB4IN88US=> M1nFc|E5OzB|OES5
KB-VIN10 cells MXPQdo9tcW[ncnH0bY9vKGG|c3H5 NEfKeZg4OiCq MnLNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQj3WTW4yOCClZXzsd{BwfmW{LXX4dJJme3OrbnegVE1oeCBzN{CvUWRTOSCjZoTldkA4OiCqcoOgZpkhdWW2aIns[Y5mKGKudXWgZZN{[XluIFnDOVA:OC5yMEC3JO69VQ>? NFLu[|IzOTZ2MUewNC=>
HCT116 cells M3vxU2N6fG:2b4jpZ4l1gSCjc4PhfS=> NIPRWGE4OiCq MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByMEe0JO69VQ>? Mo\ENlE6PTV2NUS=
DU145 cells MonZR5l1d3SxeHnjbZR6KGG|c3H5 NIDhVFc1QCCq NWm4bmgyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMEig{txO NF74V5EyQDNyM{i0PS=>
RS4:11 cells MWTQdo9tcW[ncnH0bY9vKGG|c3H5 M4PwblczKGh? Mon6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUU{S6NVEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IDizMUg1NDVvZHnt[ZRpgWy2aHnhfo9tNTJveXypMVItPS2maYDo[Y56dHSndILhfo9tcXWvIHLyc41q\GVidHXzeEwhUUN3ME2wMlAxODhizszN MnP5NlU4QDV4MEW=
HCT 116 M1TIfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYrDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBpfW2jbjDjc4xwdiC2dX3vdkBJS1RiMUG2MEBKSzVyPUCuNFAxQSEQvF2= MlnSNVE4OTR4MUO=
HeLa cells M1vhd2N6fG:2b4jpZ4l1gSCjc4PhfS=> M2fnUVczKGh? MnHZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC3NkBpenNiYomgdoV{[Xq3cnnuJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD1yLkCwNFkh|ryP NIrvbHIzPDZ4OUi4PC=>
BNL 1ME A.7R.1 cells MWXDfZRwfG:6aXPpeJkh[XO|YYm= M1;v[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJPVCBzTVWgRU44Wi5zIHPlcIx{NCCLQ{WwQVAvODByOTFOwG0> NYPCPVVHOjV5OEW2NFU>
Calu6 MkHJVJJwdGmoZYLheIlwdiCjc4PhfS=> NVe5Oph1PDhiaB?= MoTuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFYXz1OkBi\nSncjC0PEBpenNiYomgd5Bm[3S{b4Doc5RwdWW2comsJGlEPTB;MD6wNFA6PCEQvF2= NXfTO5JxOjF5N{S0PVk>
melanoma B16 cell NHLDOXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGHnfW9Ed26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCvdYLpcoUhdWWuYX7vcYEhSjF4IHPlcIwhdGmwZTygTWM2OD1yLkCwNUDPxE1? MnPONVE4OTR4MUO=
DU145 cells NUm0WpF[S3m2b4TvfIlkcXS7IHHzd4F6 M1uyNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? MYGyNFQ6Pjl{Mx?=
HCT116 cells NWXRZ|NKWHKxbHnm[ZJifGmxbjDhd5NigQ>? NIm5RZM4OiCq M3jxNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEh|ryP Mki2NlEyOTJzM{C=
HCT15 cells MV;Qdo9tcW[ncnH0bY9vKGG|c3H5 M1\iSFczKGh? MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEG1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEGg{txO Mny1NlEyOTJzM{C=
HL60 cells M{DpNnBzd2yrZnXyZZRqd25iYYPzZZk> NUC1PYFSPzJiaB?= MkLrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP M33MVFIyPjZ|M{G5
A10 cells MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1T3SFQ5KGh? MUfHdo94fGhiaX7obYJqfGmxbjDv[kBz[XRiQUGwJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO Mmm4NlIxPDRzNkS=
HUVEC cells MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmHvOFghcA>? MUDHdo94fGhiaX7obYJqfGmxbjDv[kBJXV[HQzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> M1\ZOlIzODR2MU[0
HL60 cells NGGxO2hEgXSxdH;4bYNqfHliYYPzZZk> NFfmZ|c4OiCq NFzhRlVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN NIjXWFIzOjF|NkOxNi=>
HL60 cells NHzzW|ZRem:uaX\ldoF1cW:wIHHzd4F6 MY[3NkBp MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MVGyNlU4QDFzMR?=
NCI-H522 cells M2\kdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{ftOVQ5KGh? MVPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDV{MjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> M3rDUlIzQTh{MUKy
MDA-MB-435 cells NWTlOXlxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYrrRY9UPDhiaB?= NVTsZXAyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= MkTrNlI6QDJzMkK=
OVCAR3 Mlr3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFTBWZg1QCCq MYrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDPWmNCWjNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= NWDLb3dDOjJ7OEKxNlI>
NCI/ADR-RES cells MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV20PEBp MnXQS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? NUPIXWtKOjJ7OEKxNlI>
PC3 cells NHzyU|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUTF[nBLPDhiaB?= M{nmdmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= MlTBNlI6QDJzMkK=
DU145 cells NGjN[VdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmfiOFghcA>? MojqS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= NILjZ5gzOjl6MkGyNi=>
MDA-MB-231 cells MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUC0PEBp M{mydmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? MUGyNlk5OjF{Mh?=
CEM cells MmnvR5l1d3SxeHnjbZR6KGG|c3H5 MYS3NkBp MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NXrqO4pJOjJ4N{[yOFc>
HCT116 cells Mn7ER5l1d3SxeHnjbZR6KGG|c3H5 Ml7EO|IhcA>? NYfNWoUzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NXzFRoRIOjJ4N{[yOFc>
MDA-MB-435 cells MW\DfZRwfG:6aXPpeJkh[XO|YYm= NXLoUYNzPzJiaB?= M4\IRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MUiyNlY4PjJ2Nx?=
HaCaT cells NGHVRYdRem:uaX\ldoF1cW:wIHHzd4F6 NFHQOnRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjhR4FVKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> NFfjN28zOzB4M{SwNS=>
HL60 cells M2j3UHBzd2yrZnXyZZRqd25iYYPzZZk> MXG3NkBp NFjucVZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? Mn3rNlMyOTdzN{G=
HL60 cells M2\meHBzd2yrZnXyZZRqd25iYYPzZZk> M3rzSVczKGh? MnrNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSBqMz2oOEw2NWSrbXX0bJltfGirYYrvcE0zNXmuKT2yMFUu\GmyaHXufYx1\XS{YYrvcIl2dSCkcn;tbYRmKHSnc4SsJGlEPTB;MD6wNFEh|ryP M1\udVI2Pzh3NkC1
HT-29 MlrKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlLPS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MUWyOVY5QTFzMR?=
HL60 cells M13ORnBzd2yrZnXyZZRqd25iYYPzZZk> NIDlNpY4OiCq NFPzWFBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NX7TO2ZVOjB2MkC0N|k>
Hs578T cells MnXxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVO0PEBp NIr3N4VIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJezV5OGSgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> NEm5UGczOjl6MkGyNi=>
HL60 cells NVGzPFV{S3m2b4TvfIlkcXS7IHHzd4F6 MoLoO|IhcA>? NHO1[ZNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN NEH5dm0zOzR2NUS5Oi=>
SKOV3 cells M2rhVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mnf5S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tQXjNiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MnvGNlU3QDlzMUG=
MDA-MB-468 cells MUfDfZRwfG:6aXPpeJkh[XO|YYm= Mn:0OEBl[Xm| MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDRiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEGxJO69VQ>? M1nu[lI1OjFyNUCz
MCF7 cells MXjQdo9tcW[ncnH0bY9vKGG|c3H5 M1jTO|czKGh? MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEyOSEQvF2= M3mzVlIzOzJ7NU[x
H460 MkHHR5l1d3SxeHnjbZR6KGG|c3H5 MlLwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKHSnc4SsJGlEPTB;MD6wNFEzKM7:TR?= M3XpNFE5Pzh|MkC3
H460 M4D5VnBzd2yrZnXyZZRqd25iYYPzZZk> NVXRNIttSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzMEBKSzVyPUCuNFAyOjRizszN MnTsNVY4OjJ4M{O=
NCI-H460 cells NWq5ZZl7S3m2b4TvfIlkcXS7IHHzd4F6 MYi3NkBp M4D5bmN6fG:2b4jpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJJRme3RuIFnDOVA:OC5yMEGzJO69VQ>? NG\EelkyQDN7Nki1Oy=>
OVCAR8 cells MnnYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn3PPVYhcA>? MlLNS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gU3ZESVJ6IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHAu\2y7Y3;wdo91\WmwIHHmeIVzKDl4IHjyd{whUUN3ME2wMlAxOTNizszN M365RVIzODR2MU[0
NCI/ADR-RES cells MWTDfZRwfG:6aXPpeJkh[XO|YYm= NX3pbGFtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLL1HEVk1TTVNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYomgeJJ6eGGwIHLseYUh\XilbIXzbY9vKGG|c3H5MEBKSzVyPUCuNFAyOyEQvF2= MUiyN|IyPDR3Mh?=
OVCAR8 cells MlXBR5l1d3SxeHnjbZR6KGG|c3H5 M{jvSVk3KGh? MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjhiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhQTZiaILzJIJ6KEerZX3zZUB{fGGrbnnu[{1j[XOnZDDsbYdpfCCvaXPyc5Nkd3C7LDDJR|UxRTBwMECxN{DPxE1? MkfJNlUxOjV7OUG=
NCI/ADR-RES cells MYDDfZRwfG:6aXPpeJkh[XO|YYm= M1jSNVk3KGh? MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC5OkBpenNiYomgS4lmdXOjIIP0ZYlvcW6pLXLhd4VlKGyrZ3j0JI1q[3Kxc3PvdJktKEmFNUC9NE4xODF|IN88US=> MU[yOVAzPTl7MR?=
OVCAR8 cells MkKzR5l1d3SxeHnjbZR6KGG|c3H5 M3PZcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUODDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDifUB1enmyYX6gZox2\SCneHPseZNqd25iYYPzZZktKEmFNUC9NE4xODF|IN88US=> M3HDTlI{OjF2NEWy
HuTu 80 cells MXrQdo9tcW[ncnH0bY9vKGG|c3H5 MmfIO|IhcA>? MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDIeXR2KDhyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODF|NzFOwG0> M2H2R|IzOzJ7NU[x
K562 cells NXeyR4ZiS3m2b4TvfIlkcXS7IHHzd4F6 NUG5elVTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyxiSVO1NF0xNjByMUSg{txO Mn2zNVk5Ozd3OUS=
NCI/ADR (MDR) cells Mn60SpVv[3Srb36gZZN{[Xl? M3;1bWNmdGxiY4njcIUh[XK{ZYP0JIlvKE6FST;BSHIhME2GUjmgZ4VtdHNiYomgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WsJGlEPTB;MD6wNFE2KM7:TR?= M{DySFE3Ozd5MUi3
HUVEC MWTQdo9tcW[ncnH0bY9vKGG|c3H5 NWnnTFVDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWXZGSyxiSVO1NF0xNjByMUWg{txO MYGxOlczOjZ|Mx?=
KB cell M4rW[XBzd2yrZnXyZZRqd25iYYPzZZk> NYfpVZZzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuIHzpcoUh[nlibXX0bJlt\W6nIHLseYUh\HmnIHHzd4F6NCCLQ{WwQVAvODBzNTFOwG0> M2TISVE4ODN2MUS3
KB-VIN10 cell NEDoUXlRem:uaX\ldoF1cW:wIHHzd4F6 MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuELW\JUlExKGOnbHygcIlv\SCkeTDt[ZRpgWynbnWgZox2\SCmeXWgZZN{[XluIFnDOVA:OC5yMEG1JO69VQ>? NX3lPHR7OTdyM{SxOFc>
Human SH-SY5Y neuroblastoma cells M2eyfWZ2dmO2aX;uJIF{e2G7 M37oTGlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IFj1cYFvKFOKLWPZOXkhdmW3cn;icIF{fG:vYTDj[YxteyxiSVO1NF0xNjByMUWg{txO MkH1NVU6PjN5MkK=
SW620 cells Ml\3VJJwdGmoZYLheIlwdiCjc4PhfS=> MVm3NkBp MmLvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gV3c3OjBiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOTV{IN88US=> NWTQNZpiOjJ|Mkm1OlE>
Molt4/C8 cells NYq4ZWNIWHKxbHnm[ZJifGmxbjDhd5NigQ>? NIrkbIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3vcJQ1N0N6IHPlcIx{NCCLQ{WwQVAvODBzNjFOwG0> MV6xO|A{PDF3MB?=
ACHN cell M4f6cnBzd2yrZnXyZZRqd25iYYPzZZk> NELzU2FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIRzfWdicnXzbZN1[W62IFHDTG4h[2WubDDsbY5mKGW6cILld5NqdmdiTVTSNUBjgSCDbHHtZZIhSmy3ZTDhd5NigSxiSVO1NF0xNjByMU[g{txO MnzyNVczQDZ|OUO=
Molt4/C8 cells NUDGSpV6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NIXTWYw{KGSjeYO= M1O2WWFvfGmycn;sbYZmemG2aY\lJIVn\mWldDDh[4FqdnO2IHj1cYFvKE2xbIS0M2M5KGOnbHzzJIFnfGW{IEOg[IF6eyxiSVO1NF0xNjByMU[g{txO MmTvNVc1OTl4MEe=
In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol (from reference)

Kinase Assay:[1]
  • Competitive binding assay using LC-MS/MS:

    Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.

Cell Research:[1]
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
Animal Research:[2]
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Dosages: 100 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.

30mg/mL

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How to make solution for in vivo IP injection?

Answer:
We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor